NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

Published:2021-11 Issue:11 Volume:19 Page:1218-1230
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Zelenetz Andrew D.¹,Gordon Leo I.²,Chang Julie E.³,Christian Beth⁴,Abramson Jeremy S.⁵,Advani Ranjana H.⁶,Bartlett Nancy L.⁷,Budde L. Elizabeth⁸,Caimi Paolo F.⁹,De Vos Sven¹⁰,Dholaria Bhagirathbhai¹¹,Fakhri Bita¹²,Fayad Luis E.¹³,Glenn Martha J.¹⁴,Habermann Thomas M.¹⁵,Hernandez-Ilizaliturri Francisco¹⁶,Hsi Eric⁹,Hu Boyu¹⁴,Kaminski Mark S.¹⁷,Kelsey Christopher R.¹⁸,Khan Nadia¹⁹,Krivacic Susan²⁰,LaCasce Ann S.²¹,Lim Megan²²,Narkhede Mayur²³,Rabinovitch Rachel²⁴,Ramakrishnan Praveen²⁵,Reid Erin²⁶,Roberts Kenneth B.²⁷,Saeed Hayder²⁸,Smith Stephen D.²⁹,Svoboda Jakub²²,Swinnen Lode J.³⁰,Tuscano Joseph³¹,Vose Julie M.³²,Dwyer Mary A.³³,Sundar Hema³³

Affiliation:

1. 1Memorial Sloan Kettering Cancer Center;

2. 2Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

3. 3University of Wisconsin Carbone Cancer Center;

4. 4The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

5. 5Massachusetts General Hospital Cancer Center;

6. 6Stanford Cancer Institute;

7. 7Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

8. 8City of Hope National Medical Center;

9. 9Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

10. 10UCLA Jonsson Comprehensive Cancer Center;

11. 11Vanderbilt-Ingram Cancer Center;

12. 12UCSF Helen Diller Family Comprehensive Cancer Center;

13. 13The University of Texas MD Anderson Cancer Center;

14. 14Huntsman Cancer Institute at the University of Utah;

15. 15Mayo Clinic Cancer Center;

16. 16Roswell Park Comprehensive Cancer Center;

17. 17University of Michigan Rogel Cancer Center;

18. 18Duke Cancer Institute;

19. 19Fox Chase Cancer Center;

20. 20Consultant;

21. 21Dana-Farber/Brigham and Women’s Cancer Center;

22. 22Abramson Cancer Center at the University of Pennsylvania;

23. 23O'Neal Comprehensive Cancer Center at UAB;

24. 24University of Colorado Cancer Center;

25. 25UT Southwestern Simmons Comprehensive Cancer Center;

26. 26UC San Diego Moores Cancer Center;

27. 27Yale Cancer Center/Smilow Cancer Hospital;

28. 28Moffitt Cancer Center;

29. 29Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

30. 30The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

31. 31UC Davis Comprehensive Cancer Center;

32. 32Fred & Pamela Buffett Cancer Center; and

33. 33National Comprehensive Cancer Network.

Abstract

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/19/11/article-p1218.xml

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma;Frontiers in Oncology;2024-02-01

2. The Gut Microbiome Correlated to Chemotherapy Efficacy in Diffuse Large B-Cell Lymphoma Patients;Hematology Reports;2024-01-22

3. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients;BMC Immunology;2024-01-13

4. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort;Blood Advances;2024-01-10

5. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors;International Forum of Allergy & Rhinology;2024-01-02